Changes in survival and time to progression in metastatic breast cancer (MBC) patients enrolled into clinical trials from 1983 to 2001.

被引：0
|
作者：
Gennari, A
Conte, P
Orlandini, C
Guarneri, V
Rosso, R
Bruzzi, P
机构：
[1] Div Med Oncol, Pisa, Italy
[2] Div Med Oncol, Modena, Italy
[3] NCI, Genoa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
634
引用
收藏
页码：35S / 35S
页数：1
相关论文
共 50 条
  • [21] Inappropriate doses of chemotherapy in Italian breast cancer patients enrolled in clinical trials
    Ballatori, Enzo
    Roila, Fausto
    Ruggeri, Benedetta
    De Angelis, Verena
    Porzio, Giampiero
    Marchetti, Paolo
    TUMORI, 2007, 93 (06) : 540 - 543
  • [22] Why aren't more patients with breast cancer enrolled in clinical trials?
    Lalor, Fallon
    Caston, Nicole E.
    Ingram, Stacey A.
    Wan, Clara
    Sussell, Jesse
    Patel, Shilpen A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 84 - 84
  • [23] Enrollment of older metastatic breast cancer patients in clinical trials
    Bringuier, Michael
    Carton, Matthieu
    Levy, Christelle
    Patsouris, Anne
    Pasquier, David
    Debled, Marc
    Rigal, Olivier
    Jacot, William
    Goncalves, Anthony
    Desmoulins, Isabelle
    Rouge, Thibault De La Motte
    Bachelot, Thomas
    Ferrero, Jean-Marc
    Eymard, Jean-Christophe
    Dalenc, Florence
    Mouret-Reynier, Marie-Ange
    Petit, Thierry
    Chevrot, Michael
    Courtinard, Coralie
    Uwer, Lionel
    Frenel, Jean-Sebastien
    Baldini, Capucine
    CANCER RESEARCH, 2021, 81 (04)
  • [24] EFFECT OF REDUCTION OF CIRCULATING TUMOR CELLS (CTCS) ON PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN METASTATIC BREAST CANCER (MBC) PATIENTS
    Giuliano, M.
    Giordano, A.
    Handy, B. C.
    Ueno, N.
    Andreopoulou, E.
    Alvarez, R. H.
    Valero, V.
    Hortobagyi, G. N.
    Reuben, J.
    Cristofanilli, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 32 - 33
  • [25] Survival and clinical outcomes of ovarian cancer patients enrolled in phase I clinical trials.
    Corr, Bradley
    Moroney, Marisa
    Sheeder, Jeanelle
    Sawyer, Brandon
    Eckhardt, S. Gail
    Behbakht, Kian
    Diamond, Jennifer Robinson
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Impact of CNS metastases on treatment and survival in patients receiving trastuzumab for metastatic breast cancer (MBC)
    Griffiths, R.
    Lindquist, K.
    Lalla, D.
    Doan, J. F.
    Brammer, M. G.
    Danese, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] The effect of age on overall survival (OS) in patients with metastatic breast cancer (MBC) treated with capecitabine
    Blum, J. L.
    Hu, X.
    Odom, D.
    Sherrill, B.
    Glueck, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] First data on overall survival of metastatic breast cancer patients in Austria according to breast cancer subtype: results from the AGMT MBC Registry
    Rinnerthaler, G.
    Gampenrieder, S. P.
    Petzer, A.
    Tinchon, C.
    Fuchs, D.
    Balic, M.
    Heibl, S.
    Rumpold, H.
    Egle, D.
    Zabernigg, A. F.
    Singer, C. F.
    Andel, J.
    Hubalek, M.
    Knauer, M.
    Greil, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 40 - 40
  • [29] ANALYSIS OF ERIBULIN MESYLATE UTILZATION IN PATIENTS WITH METASTATIC BREAST CANCER (MBC) BY LINE OF THERAPY AND ASSOCIATED CHANGES OVER TIME
    Feinberg, B. A.
    Drenning, J.
    Garofalo, D. F.
    Montgomery, J.
    VALUE IN HEALTH, 2015, 18 (07) : A479 - A480
  • [30] Predictors of survival in patients with HER2+metastatic breast cancer (MBC) treated with trastuzumab
    Olson, E. M.
    Najita, J. S.
    Sohl, J.
    Arnaout, A.
    Winer, E. P.
    Lin, N. U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345